WO2021145113A1 - 抗老化用組成物 - Google Patents

抗老化用組成物 Download PDF

Info

Publication number
WO2021145113A1
WO2021145113A1 PCT/JP2020/046210 JP2020046210W WO2021145113A1 WO 2021145113 A1 WO2021145113 A1 WO 2021145113A1 JP 2020046210 W JP2020046210 W JP 2020046210W WO 2021145113 A1 WO2021145113 A1 WO 2021145113A1
Authority
WO
WIPO (PCT)
Prior art keywords
aging
bacterium
culture
cells
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2020/046210
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
一弥 戸田
和也 大野
真 吉本
恵梨 密山
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morinaga Milk Industry Co Ltd
Original Assignee
Morinaga Milk Industry Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morinaga Milk Industry Co Ltd filed Critical Morinaga Milk Industry Co Ltd
Priority to JP2021570686A priority Critical patent/JP7419404B2/ja
Priority to EP20913307.3A priority patent/EP4091673A4/en
Publication of WO2021145113A1 publication Critical patent/WO2021145113A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/38—Other non-alcoholic beverages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
    • C12P1/04—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales

Definitions

  • the present invention relates to an anti-aging composition.
  • Cell aging is generally defined as a condition in which cells remain viable and have metabolic activity but lose their ability to proliferate. The number of times mammalian cells can divide and proliferate is finite, and when the number of cell divisions reaches the end of their lifespan (limit number), cellular senescence is induced. When cells isolated from the elderly and cells isolated from the young are cultured in vitro and the number of cell divisions is compared, it is known that the cells isolated from the elderly reach the divisional lifespan earlier.
  • Cellular senescence also includes telomere shortening due to DNA terminal replication, DNA damage, changes in the expression and activity of tumor suppressor genes and tumor genes, oxidative stress, inflammation, chemotherapeutic agents, exposure to UV irradiation and ionizing radiation, etc. It is known that it can be caused by various stimuli or factors (Non-Patent Document 1).
  • SASP Senescence Associated Secretory Phenotype
  • Non-Patent Document 2 Due to these properties of senescent cells, there is increasing interest in preventing the accumulation of senescent cells (Senolytics), and senolytic removal of senescent cells is effective for some age-related diseases. This has been shown in animal experiments and human clinical studies (Non-Patent Document 2). Furthermore, in the mouse model, the longevity-prolonging effect of Senolytic has been shown, and the anti-aging effect at the individual level has been clarified (Non-Patent Document 3). Thus, it is suggested that cellular senescence plays an important role in individual aging.
  • Non-Patent Document 4 Systemic aging symptoms are promoted in mice that have actually induced muscular mitochondrial dysfunction (Non-Patent Document 5).
  • the increase in dysfunctional mitochondria with aging is considered to be one of the factors that cause excessive accumulation of free radicals.
  • excessive accumulation of free radicals is well known as one of the stresses that cause cell aging. Therefore, it is said that a component capable of improving mitochondrial function can be useful for anti-aging.
  • SOD superoxide dismutase
  • ROS reactive oxygen species
  • An object of the present invention is to provide a composition for anti-aging.
  • one aspect of the present invention is an anti-aging composition containing one or more selected from Bifidobacterium longum NITE BP-02621, a culture of the bacterium, and a treated product of the bacterium.
  • the anti-aging may be due to a cell aging inhibitory action and / or a mitochondrial function improving action.
  • the composition of this embodiment may be used for prolonging life and / or suppressing deterioration of motor function.
  • Another aspect of the invention comprises one or more selected from Bifidobacterium longum NITE BP-02621, a culture of the bacterium, a treated product of the bacterium, used for anti-aging. It is a composition.
  • the composition of the present invention is preferably a food or drink.
  • the composition of the present invention is preferably a pharmaceutical product.
  • Another aspect of the present invention is the use of one or more selected from Bifidobacterium longum NITE BP-02621, a culture of the bacterium, and a treated product of the bacterium in the production of an anti-aging composition. Is. Another aspect of the invention is the use of one or more selected from Bifidobacterium longum NITE BP-02621, a culture of the bacterium, a treated product of the bacterium in anti-aging. Another aspect of the present invention comprises administering to a subject one or more selected from Bifidobacterium longum NITE BP-02621, a culture of the bacterium, a treated product of the bacterium. The method.
  • an anti-aging effect can be obtained, for example, by inhibiting cell aging and / or improving mitochondrial function. Therefore, it is possible to extend the life span and suppress the deterioration of motor function.
  • composition of the present invention contains one or more selected from Bifidobacterium longum NITE BP-02621, the culture of the bacterium, and the treated product of the bacterium.
  • Bifidobacterium Longum NITE BP-02621 is located at the National Institute of Technology and Evaluation Patent Microorganisms Depositary Center (NPMD) (Room 2-5-8, 122, Kazusakamatari, Kisarazu City, Chiba Prefecture, 292-0818), 2018. An international deposit was made based on the Budapest Treaty with the accession number of NITE BP-02621 on January 26, 2014. Bifidobacterium longum NITE BP-02621 is also referred to as "BB536". The same bacterium, Bifidobacterium longum subsp.
  • ATCC BAA-999 Longum ATCC BAA-999 (number: ATCC BAA-999), is the American Type Culture Collection (ATCC; USA, 20110, Manassas, Virginia, Virginia, Virginia, It is available as ATCC BAA-999 from Manassas, VA 20110, United States of America) (see, for example, Japanese Patent Application Laid-Open No. 2012-223134).
  • the Bifidobacterium longum NITE BP-02621 is not limited to the strain itself (hereinafter, also referred to as “deposited strain” for convenience of explanation) that has been deposited or registered with a predetermined institution under the name of the bacterium.
  • deposited strain for convenience of explanation
  • Substantially equivalent strains also referred to as “derivative strains” or “derivative strains” are also included. That is, the stock itself is not limited to the stock itself deposited with the depositary institution with the deposit number, and stocks substantially equivalent thereto are also included.
  • a strain substantially equivalent to the above-mentioned deposit strain belongs to the same species as the above-mentioned deposit strain, and the similarity of the genome sequence (Average Nucleotide Identity value) with the above-mentioned deposit strain is preferably 99.
  • a strain substantially equivalent to the above-mentioned deposit strain may be, for example, a derivative strain having the deposit strain as a parent strain. Derivative strains include strains bred from deposit stocks and strains naturally generated from deposit stocks.
  • Examples of the breeding method include modification by a genetic engineering method and modification by mutation treatment.
  • Mutation treatment includes irradiation with X-rays, irradiation with ultraviolet rays, and treatment with mutant agents such as N-methyl-N'-nitro-N-nitrosoguanidine, ethylmethanesulfonate, and methylmethanesulfonate. Be done.
  • Examples of naturally occurring strains from the deposited strains include strains naturally occurring during the use of the deposited strains. Examples of such a strain include a mutant strain naturally generated by culturing a deposited strain (for example, subculture).
  • the derivative strain may be constructed by one type of modification, or may be constructed by two or more types of modification.
  • the Bifidobacterium longum NITE BP-02621 to be contained in the composition of the present invention a commercially available product may be used, one obtained by appropriately producing the product may be used, or the above-mentioned Bifidobacterium longum may be used. Those obtained by culturing NITE BP-02621 may be used.
  • the culture method is not particularly limited as long as Bifidobacterium longum NITE BP-02621 can grow.
  • the method usually used for culturing Bifidobacterium longum NITE BP-02621 can be used as it is or after being appropriately modified.
  • the culture temperature may be, for example, 25 to 50 ° C, preferably 35 to 42 ° C.
  • the culture can be preferably carried out under anaerobic conditions, and can be carried out, for example, while aerating an anaerobic gas such as carbon dioxide.
  • the culture can also be carried out under microaerobic conditions such as liquid static culture. Culturing can be carried out, for example, until Bifidobacterium longum NITE BP-02621 grows to the desired degree.
  • the medium used for culturing is not particularly limited as long as Bifidobacterium longum NITE BP-02621 can grow.
  • the medium for example, the medium normally used for culturing Bifidobacterium longum NITE BP-02621 can be used as it is or after being appropriately modified. That is, as the carbon source, for example, saccharides such as galactose, glucose, fructose, mannose, cellobiose, maltose, lactose, sucrose, trehalose, starch, starch hydrolyzate, and waste sugar honey can be used depending on the assimilation property. ..
  • ammonium salts such as ammonia, ammonium sulfate, ammonium chloride and ammonium nitrate and nitrates
  • inorganic salts for example, sodium chloride, potassium chloride, potassium phosphate, magnesium sulfate, calcium chloride, calcium nitrate, manganese chloride, ferrous sulfate and the like can be used.
  • organic components such as peptone, soybean flour, defatted soybean meal, meat extract, and yeast extract may be used.
  • fortified Clostridia medium Reinforced Clostridial medium
  • MRS medium deMan, Rogosa, and Sharpe medium
  • mMRS medium Modified MRS medium
  • TOSP medium TOSpropionatemedium
  • TOSPMup medium TOSpropionatemupirocinmedium
  • GAM GifuAnaerobicMedium
  • YCFA Yeast Extract-caseinHydrolysateAcid
  • the form of Bifidobacterium longum NITE BP-02621 contained in the composition of the present invention may be any of bacterial cells, bacterial cultures, and bacterial treatments.
  • the bacterial cells are usually preferably contained in a form containing live bacterial cells, but are not particularly limited.
  • the bacterial cell may be, for example, a live bacterial cell, a dead bacterial cell, or a mixture of a live bacterial cell and a dead bacterial cell.
  • the bacterial culture for example, the culture obtained by the culture may be used as it is, the culture may be diluted or concentrated and used, or the bacterial cells recovered from the culture may be used. Moreover, you may use culture supernatant or culture fraction as a culture.
  • the culture supernatant for example, the supernatant of the culture solution obtained by culturing in GAM medium under the conditions of 37 ° C. and 16 hours can be preferably used.
  • the processed product of bacteria crushing, heating, freeze-drying, and dilutions, dried products or fractions thereof can be used for bacterial cells or cultures.
  • the composition of the present invention can exert an anti-aging effect.
  • Anti-aging refers to preventing, suppressing, or delaying progression of age-related changes, usually undesired changes.
  • the anti-aging effect exhibited by the composition of the present invention may be due to a cell aging inhibitory effect.
  • Inhibition of cellular senescence includes inhibiting the transformation of normal cells into senescent cells.
  • normal cell is meant a cell that remains viable and has metabolic activity and proliferative capacity.
  • Aging cell means a cell in which cell senescence is induced, which is a state in which a viable state is maintained and a state in which a metabolic activity is exhibited but a proliferative ability is lost.
  • the anti-aging effect exhibited by the composition of the present invention may be due to an effect of improving mitochondrial function.
  • mitochondrial function When mitochondrial function is abnormal, active oxygen (ROS) is overproduced, damaging cells and accelerating aging. Therefore, improving mitochondrial function can result in anti-aging effects.
  • ROS active oxygen
  • functional improvement includes functional improvement, and also includes prevention, suppression, or delay of functional deterioration.
  • the mitochondrial function can usually be determined using the amount of ROS produced as an index.
  • functional deterioration includes functional abnormalities.
  • the anti-aging effect exhibited by the composition of the present invention may be due to the anti-oxidative stress improving effect.
  • oxidative stress refers to a damaging effect on cells or individuals caused by reactive oxygen species such as free radicals.
  • the antioxidant stress-improving action means increasing the resistance of cells or individuals to oxidative stress.
  • improvement usually means increasing the antioxidant stress, but may include preventing, suppressing, or delaying the decrease of the antioxidant stress.
  • the resistance to oxidative stress can be judged by using the expression level of a gene (oxidative stress resistance gene) involved in repairing damage caused by reactive oxygen species as an index.
  • antioxidant stress is synonymous with oxidative stress tolerance.
  • an anti-aging effect can be brought about by enhancing the function of repairing damage caused by oxidative stress, that is, resistance to oxidative stress.
  • abnormal mitochondrial function can provide anti-aging effects by increasing resistance to damage from overproduced reactive oxygen species.
  • life expectancy extension may include extension of healthy life expectancy as well as simply longevity.
  • the composition of the present invention can inhibit the induction from normal cells to senescent cells and suppress the accumulation of senescent cells as described above, it is related to cellular senescence or SASP secreted from senescent cells. It is expected to improve or prevent the resulting disease or symptom.
  • diseases and symptoms include premature aging, cataracts, alopecia, cardiac hypertrophy, fatty liver, interstitial pneumonia, COPD, renal glomerulosclerosis, arteriosclerosis, arthritis, disc degeneration, sarcopenia, inflammatory bowel disease, diabetes, etc. Examples include metabolic syndrome, cancer, sarcoma, lymphoma, dementia, pituitary tumor, neurodegenerative disease and the like.
  • the composition of the present invention is expected to have effects such as alleviation of bone loss, atrophy of adipose tissue, improvement of cardiac function, recovery of respiratory function, and muscle strengthening.
  • composition of the present invention can improve mitochondrial function as described above, it is expected to improve or prevent diseases or symptoms associated with or caused by abnormalities in mitochondrial function.
  • diseases and symptoms include mitochondrial diseases, musculoskeletal disorders, skin diseases, diabetes, metabolic diseases, neurodegenerative diseases, ophthalmic diseases, atherosclerosis, cardiovascular diseases, heart diseases, kidney diseases and the like. ..
  • composition of the present invention has an antioxidant stress improving effect as described above, it is expected to improve or prevent diseases or symptoms caused by oxidative stress.
  • diseases and symptoms include hypertension, inflammation, arteriosclerosis, aging phenomena such as wrinkles and sagging, neurological diseases such as cancer and Alzheimer's disease, respiratory diseases such as asthma, cataracts, heart disease, and digestive organs such as fatty liver. Symptoms such as illness, loss of concentration and feeling of fatigue can be mentioned.
  • the content of Bifidobacterium longum NITE BP-02621, the culture of the bacterium, and the processed product of the bacterium in the composition of the present invention is not particularly limited, but for example, 1 mL of the composition is used as the amount of cells of the bacterium. It is preferably 1.0 ⁇ 10 4 cfu or more, and more preferably 2.0 ⁇ 10 7 cfu or more.
  • cfu refers to a colony forming unit. In the present specification, for example, it can be the value when cultivated at 38 ° C. in a solid medium containing 10% by mass of reduced skim milk powder. Further, when the cells are dead cells, cfu can be replaced with individual cells (cells).
  • the culture supernatant When used as the culture of the bacterium, it is preferably 0.1 to 100% by mass, more preferably 1 to 90% by mass, and further preferably 10 to 80% by mass of the entire composition. Can be. These may usually be in the range of content when distributed as an oral composition.
  • Another aspect of the invention comprises one or more selected from Bifidobacterium longum NITE BP-02621, a culture of the bacterium, a treated product of the bacterium used for anti-aging. It is a composition.
  • Another aspect of the present invention is the use of one or more selected from Bifidobacterium longum NITE BP-02621, said bacterial cultures, said bacterial treated products in the production of anti-aging compositions. Is.
  • Another aspect of the invention is the use of one or more selected from Bifidobacterium longum NITE BP-02621, cultures of the bacterium, and treatments of the bacterium in anti-aging.
  • Another aspect of the present invention is one or more selected from Bifidobacterium longum NITE BP-02621, a culture of the bacterium, a treated product of the bacterium, which is used for anti-aging.
  • Another aspect of the invention is anti-aging, comprising administering to a subject one or more selected from Bifidobacterium longum NITE BP-02621, a culture of the bacterium, a treated product of the bacterium. The method.
  • composition of the present invention administered (administrator) and the subject to be ingested (ingestor) are not particularly limited as long as they are animals, but are usually humans. In addition, it may be any of adults, children, infants, newborns (including low-weight babies), etc., but is usually an adult.
  • the gender is not particularly limited.
  • administering one or more kinds selected from Bifidobacterium longum NITE BP-02621, the culture of the bacterium, and the processed product of the bacterium to an animal means “Bifido”. It may be synonymous with “ingesting one or more species selected from Bacterial Longum NITE BP-02621, the culture of the bacterium, and the processed product of the bacterium”. Ingestion is usually voluntary (free ingestion), but may be compulsory (compulsory ingestion).
  • the administration step for example, one or more selected from Bifidobacterium longum NITE BP-02621, the culture of the bacterium, and the processed product of the bacterium are added to foods and drinks and feeds. It may be a step of blending and supplying to the subject, thereby allowing the subject to freely ingest it.
  • the ingestion (administration) timing of the composition of the present invention is not particularly limited, and can be appropriately selected according to the condition of the ingestion (administration) target.
  • the ingestion (administration) amount of the composition of the present invention is appropriately selected depending on the age, gender, condition, other conditions, etc. of the ingestion (administration) subject.
  • the intake (administration) amount of the composition of the present invention is, for example, 0.5 to 5 g / day as the intake (administration) amount of the bacterial cells of Bifidobacterium longum NITE BP-02621 according to the present invention.
  • the range is preferred, the range of 1 to 4 g / day is more preferred, and 2 to 3 g / day is even more preferred.
  • the intake (administration) amount of the culture supernatant of Bifidobacterium longum NITE BP-02621 is preferably in the range of 0.5 to 5 g / day, more preferably in the range of 1 to 4 g / day, for example, in adults. 2-3 g / day is more preferable.
  • the composition of the present invention can be ingested (administered) once or in a plurality of times a day regardless of the amount and duration of ingestion (administration).
  • the ingestion (administration) period of the composition of the present invention is not particularly limited. In addition, there is no particular upper limit on the intake (administration) period, and continuous and long-term intake (administration) is possible.
  • the ingestion (administration) route of the composition of the present invention may be oral or parenteral, but oral is preferable.
  • parenteral ingestion (administration) includes transdermal, intravenous injection, rectal administration, inhalation and the like.
  • composition of the present invention When the composition of the present invention is to be orally ingested (administered), it is preferably in the form of food and drink.
  • the form and properties of the food and drink are not particularly limited as long as they can be orally ingested (administered) without impairing the effects of the present invention. It can be produced by a usual method using raw materials usually used for foods and drinks, except that it contains one or more selected from the processed products of bacteria.
  • Foods and drinks may be in the form of liquid, paste, gel solid, powder, etc., for example, nutritional supplements (supplements), tablet confectionery; liquid foods (nutrition foods for tube intake); bread, macaroni, spaghetti.
  • Wheat flour products such as noodles, cake mix, fried flour, bread flour; instant noodles, cup noodles, retort / cooked foods, canned foods, microwave foods, instant soups / stews, instant miso soups / suckers, canned soups, freeze-dried foods , Other instant foods such as instant foods; canned agricultural products, canned fruits, jams and marmalades, pickles, boiled beans, dried agricultural products, processed agricultural products such as cereals (processed grain products); canned marine products, fish hams and sausages , Fishery paste products, marine delicacies, boiled fish, etc.; processed livestock products such as canned livestock / pastes, livestock ham / sausage; processed milk, dairy drinks, yogurt, lactic acid bacteria drinks, cheese, ice cream, etc.
  • Frozen foods caramel, candy, chewing gum, chocolate, cookies, biscuits, cakes, pies, snacks, crackers, Japanese confectionery, rice confectionery, bean confectionery, dessert confectionery, jelly, and other confectionery; carbonated beverages, natural fruit juice , Fruit juice drinks, soft drinks with fruit juice, fruit meat drinks, fruit drinks with fruit grains, vegetable drinks, soy milk, soy milk drinks, coffee drinks, tea drinks, powder drinks, concentrated drinks, sports drinks, nutritional drinks, alcoholic drinks, etc.
  • Favorite beverages such as favorite beverages, baby foods, sprinkles, other commercial foods such as Ochazuke paste; prepared powdered milk for childcare; enteral nutritional foods; functional foods (foods for specified health use, nutritionally functional foods), etc. ..
  • feed can also be used as feed as one aspect of food and drink.
  • the feed include pet food, livestock feed, fish feed and the like.
  • the form of the feed is not particularly limited, and in addition to one or more selected from Bifidobacterium longum NITE BP-02621, the culture of the bacterium, and the processed product of the bacterium, for example, corn, wheat, and the like.
  • Grains such as barley, rye, and mylo; vegetable oil cakes such as soybean oil cake, rapeseed oil cake, palm oil cake, and flaxseed oil cake; bran such as bran, wheat bran, rice bran, and defatted rice bran; Manufactured cakes; animal feeds such as fish flour, defatted milk powder, casein, yellow grease, and corn; yeasts such as tolla yeast and beer yeast; mineral feeds such as tertiary calcium phosphate and calcium carbonate; fats and oils; single amino acids; It may contain sugars and the like.
  • composition of the present invention is in the form of a food or drink (including feed), it can be provided and sold as a food or drink whose use related to anti-aging is indicated.
  • Such "display” act includes all acts for informing the consumer of the use, and if it is an expression that can recall or analogize the use, the purpose of the display, the content of the display, etc. Regardless of the object or medium to be displayed, all of them fall under the act of "displaying” in the present invention. Further, it is preferable that the "display” is performed by an expression that allows the consumer to directly recognize the above-mentioned use.
  • Examples include the act of describing the above-mentioned use and displaying or distributing it, or describing the above-mentioned use in the information containing these and providing it by an electromagnetic (Internet, etc.) method.
  • the display content is a display approved by the government or the like (for example, a display obtained based on various systems established by the government and performed in a manner based on such approval).
  • labeling includes labeling as health foods, functional foods, enteric nutritional foods, special purpose foods, health functional foods, specified health foods, nutritional functional foods, functional foods, non-pharmaceutical products, etc. Can also be mentioned. Among these, in particular, labeling approved by the Consumer Affairs Agency, for example, a system related to foods for specified health use, nutritionally functional foods, or functional foods, or labeling approved by a system similar to these can be mentioned. Specifically, labeling as a food for specified health use, labeling as a conditional food for specified health use, labeling to the effect that it affects the structure and function of the body, labeling for reducing the risk of illness, and functionality based on scientific evidence. Indications, etc.
  • Such indications include, for example, "for those who want to prevent aging”, “for improving motor function”, “for those who want to extend healthy life expectancy”, “for those who want to stay young forever”, and “antioxidant power”. "For those who want to improve”, “For those who want to increase antioxidant power”, “For those who want to increase resistance to oxidative stress”, etc.
  • the composition of the present invention can also be in the form of a pharmaceutical product.
  • the route of ingestion (administration) of the drug may be oral or parenteral, but oral is preferable.
  • parenteral ingestion (administration) includes transdermal, intravenous injection, rectal administration, inhalation and the like.
  • As the form of the drug it can be appropriately formulated into a desired dosage form according to the ingestion (administration) method.
  • a solid preparation such as a powder, a granule, a tablet or a capsule
  • a liquid preparation such as a solution, a syrup, a suspension or an emulsion.
  • parenteral ingestion In the case of parenteral ingestion (administration), it can be formulated into a suppository, an ointment, an injection, or the like.
  • components such as excipients, pH adjusters, colorants, and flavoring agents that are usually used for formulation can be used. It is also possible to use other medicines such as other medicinal ingredients and known or future anti-aging ingredients.
  • the formulation can be carried out by a known method as appropriate depending on the dosage form.
  • a carrier usually used for formulation may be blended and formulated as appropriate. Examples of such carriers include excipients, binders, disintegrants, lubricants, stabilizers, flavoring agents and the like.
  • excipients include sugar derivatives such as lactose, sucrose, glucose, mannit, and sorbit; starch derivatives such as corn starch, horse bell starch, ⁇ -starch, dextrin, and carboxymethyl starch; crystalline cellulose, hydroxypropyl cellulose, and the like.
  • Cellulous derivatives such as hydroxypropylmethyl cellulose, carboxymethyl cellulose, carboxymethyl cellulose calcium; gum arabic; dextran; purulan; silicate derivatives such as light anhydrous silicic acid, synthetic aluminum silicate, magnesium aluminometasilicate; phosphate derivatives such as calcium phosphate; carbonic acid Carbonate derivatives such as calcium; sulfate derivatives such as calcium sulfate can be mentioned.
  • binder examples include gelatin; polyvinylpyrrolidone; macrogol and the like in addition to the above-mentioned excipients.
  • disintegrant examples include, in addition to the above-mentioned excipients, chemically modified starch or cellulose derivatives such as croscarmellose sodium, carboxymethyl starch sodium, and crosslinked polyvinylpyrrolidone.
  • lubricant examples include talc; stearic acid; metal stearate salts such as calcium stearate and magnesium stearate; colloidal silica; waxes such as pea gum and silicic acid; boric acid; glycol; carboxylic acids such as fumaric acid and adipic acid.
  • Sodium carboxylic acid salts such as sodium benzoate; sulfates such as sodium sulfate; leucine; lauryl sulfates such as sodium lauryl sulfate and magnesium lauryl sulfate; silicic acids such as silicic acid anhydride and silicic acid hydrate; starch derivatives and the like. Be done.
  • the stabilizer examples include paraoxybenzoic acid esters such as methylparaben and propylparaben; alcohols such as chlorobutanol, benzyl alcohol and phenylethyl alcohol; benzalkonium chloride; acetic acid anhydride; and sorbic acid.
  • flavoring agent examples include sweeteners, acidulants, and flavors.
  • carrier used in the case of a liquid preparation for oral ingestion (administration) examples include a solvent such as water.
  • the timing of ingesting (administering) the drug of the present invention is not particularly limited, for example, before meals, after meals, between meals, and before bedtime.
  • Bifidobacterium longum NITE BP-02621 Bifidobacterium longum NITE BP-02621 (BB536) was prepared by using MRS medium (Difco Lactobacillo MRS Broth, Becton, Dickinson and Company). ) was pre-cultured. The preculture solution was inoculated into GAM medium (GAM Bouillon “Nissui", manufactured by Nissui Pharmaceutical Co., Ltd.) at 5% (v / v) and cultured at 37 ° C. for 16 hours. The culture solution was centrifuged at 4 ° C.
  • culture supernatant of Bifidobacterium longum NITE BP-02621 (BB536) is also simply referred to as "culture supernatant of BB536".
  • the culture supernatant of BB536 prepared in Example 1 was added thereto in an amount of 1% (v / v) or 0.1% (v / v), and the cells were cultured under the conditions of 37 ° C., 5% and CO 2. Eighteen hours after the start of the culture, a final concentration of 3 ⁇ M doxorubicin (Doxo; doxorubicin hydrochloride, manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.) was added, and aging-inducing stimulation was performed for 1 hour.
  • doxorubicin Doxo; doxorubicin hydrochloride, manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.
  • the cells were washed twice with 2 mL of phosphate buffered saline (PBS pH 7.4 (1X), manufactured by gibco), and 2 mL MEM medium, 10% FBS, and 1% P / S were added.
  • PBS pH 7.4 (1X) phosphate buffered saline
  • MEM medium, 10% FBS, and 1% P / S were added.
  • the MEM medium, FBS and P / S used were the same as those at the time of seeding of TIG-3 cells.
  • culture supernatant group of BB536 A well was also provided to which the culture supernatant of BB536 was not added (Dox group).
  • Dox group wells in which the culture supernatants of Dox and BB536 were not added and DMSO was added were also provided (DMSO group).
  • SA- ⁇ -Gal senescence-related acidic ⁇ -galactosidase staining was performed to specifically stain senescent cells.
  • the cells stained with SA- ⁇ -Gal were photographed at three locations using a bright-field microscope (5x objective lens), and the number of cells was counted as senescent cells.
  • gene expression analysis of p16 which is a marker for senescent cells, was performed after culturing for 72 hours after the second addition of the culture supernatant of BB536.
  • the reverse transcription reaction was performed using PrimeScript RT Reagent Kit (manufactured by Takara Bio Inc.), and qPCR was performed using TB Green Premix Ex Taq II (manufactured by Takara Bio Inc.).
  • FIG. 1 shows the ratio of the number of SA- ⁇ -Gal-stained cells to the total number of seeded cells in each group (staining rate%).
  • the Dox group 36% of SA- ⁇ -Gal-positive cells were present, whereas in the BB536 culture supernatant group (1%), SA- ⁇ -Gal-positive cells were 15%.
  • the result of the culture supernatant group of BB536 was lower than the staining rate (23%) of SA- ⁇ -Gal positive cells in the NAC group, which is a positive control.
  • FIG. 2 shows the gene expression level of p16 (relative expression level with respect to the internal control GAPDH) in each group.
  • the relative expression level was 0.0214 in the Dox group, whereas it was 0.0156 in the 1% culture supernatant administration group of BB536, which was significantly lower than that in the Dox group (Welch's t-test, p value). 0.0387). From the above results, it was found that the culture supernatant of Bifidobacterium longum NITE BP-02621 has a cell senescence inhibitory effect.
  • Bifidobacterium longum NITE BP-02621 Bifidobacterium longum NITE BP-02621 (BB536) was prepared in MRS medium (manufactured by Difco Lactobacillo MRS Broth, Becton, Dickinson and Company). was cultured at 37 ° C. under anaerobic conditions. After 16 hours of culturing, the cells were collected by centrifugation.
  • MRS medium manufactured by Difco Lactobacillo MRS Broth, Becton, Dickinson and Company
  • test plate 2'-deoxy-5-fluorouridine (manufactured by Tokyo Chemical Industry Co., Ltd.) was added to the OP50 smear NGM plate to prepare a control plate (control group). This is because the addition of 2'-deoxy-5-fluorouridine does not add new individuals.
  • Half of the normal diet OP50 was replaced with the BB536 cells recovered by the above method with respect to the control plate (BB536 cells administration group).
  • Fig. 3 shows the survival curve (lifespan) with the 3rd day (L4 / adult stage) after hatching as 0 days.
  • a remarkable life-prolonging effect was observed in the cell-administered group of BB536.
  • the average life expectancy (days) was 19.4 ⁇ 0.57 in the control group and 23.7 ⁇ 0.69 in the cell-administered group of BB536.
  • Test Example 3 Examination of motor function improving effect in old-aged nematodes The breeding of nematodes and the preparation of test plates were carried out in the same manner as in Test Example 2. Aged nematodes bred for 14 days were picked up with a platinum loop on a control plate or a test product plate, moved into M9 buffer, and the number of swinging movements for 30 seconds was measured with a microscope. The above measurement was performed one by one.
  • Table 1 shows the number of swinging movements for 30 seconds in old-age nematodes. It was found that BB536 suppressed the decline in motor function that declined with aging. The specific number of times was 24.8 ⁇ 3.3 in the control group and 33.5 ⁇ 4.0 in the cell-administered group of BB536.
  • Test Example 4 Examination of improving effect on mitochondrial dysfunction The breeding of nematodes and the preparation of test plates were carried out in the same manner as in Test Example 2. On a control plate or a test product plate, nematodes bred for 7 days are suspended in M9 buffer and seeded on a 96-well plate to induce paraquat (final concentration: 1 mM) and H2DCFDA (final concentration). 500 ⁇ M) was added and the animals were bred for 6 hours. After that, the amount of active oxygen (ROS) produced was quantified by measuring the fluorescence intensity (Ex: 480 nm / Em: 530 nm) using a plate reader, and the number of nematodes in each well was measured and corrected with a microscope. ..
  • ROS active oxygen
  • Table 2 shows the amount of ROS produced in nematodes. It was confirmed that BB536 suppressed ROS production. Specifically, it was confirmed that the BB536 cell-administered group was suppressed up to 0.40 times as much as the control.
  • Fig. 4 shows the survival curve (lifespan) with the 3rd day (L4 / adult stage) after hatching as 0 day.
  • a remarkable life-prolonging effect was observed in the cell-administered group of BB536.
  • the average life expectancy (days) was 5.01 ⁇ 0.34 in the control group and 7.16 ⁇ 0.27 in the cell-administered group of BB536.
  • the oxidative stress resistance genes heat shock protein 70 (HSP70), superoxide dismutase 1 (SOD-1), thioredoxin-1 (trx-1), and glutathione S-transferase 4 ( The expression level of gst-4) and ACT-1 as an endogenous control gene was quantitatively analyzed. The expression level of the oxidative stress resistance gene was corrected by the expression level of ACT-1.
  • Table 3 shows the expression level of the oxidative stress resistance gene in C. elegans. It was confirmed that BB536 increased the expression levels of the oxidative stress resistance genes HSP70, SOD-1, trx-1, and gst-4.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Polymers & Plastics (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Birds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Non-Alcoholic Beverages (AREA)
PCT/JP2020/046210 2020-01-17 2020-12-11 抗老化用組成物 Ceased WO2021145113A1 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021570686A JP7419404B2 (ja) 2020-01-17 2020-12-11 抗老化用組成物
EP20913307.3A EP4091673A4 (en) 2020-01-17 2020-12-11 ANTI-AGING COMPOSITION

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2020006097 2020-01-17
JP2020-006097 2020-01-17
JP2020-066742 2020-04-02
JP2020066742 2020-04-02

Publications (1)

Publication Number Publication Date
WO2021145113A1 true WO2021145113A1 (ja) 2021-07-22

Family

ID=76864207

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2020/046210 Ceased WO2021145113A1 (ja) 2020-01-17 2020-12-11 抗老化用組成物

Country Status (3)

Country Link
EP (1) EP4091673A4 (https=)
JP (1) JP7419404B2 (https=)
WO (1) WO2021145113A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116694528A (zh) * 2023-06-20 2023-09-05 广东南芯医疗科技有限公司 长双歧杆菌lf04在制备抗氧化和抗衰老产品中的应用
CN118806654A (zh) * 2024-07-17 2024-10-22 慕恩（广州）生物科技有限公司 长双歧杆菌的二裂酵母发酵产物溶胞产物及其在抗氧化及抗紫外中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011517568A (ja) * 2008-04-15 2011-06-16 ネステク ソシエテ アノニム ビフィドバクテリウム・ロンガム及び海馬ｂｄｎｆ発現
JP2012223134A (ja) 2011-04-20 2012-11-15 Morinaga Milk Ind Co Ltd 生菌数測定方法
WO2019188943A1 (ja) * 2018-03-26 2019-10-03 森永乳業株式会社 脳血流低下の予防及び／又は改善用組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106399163B (zh) * 2016-09-08 2019-09-27 江苏微康生物科技有限公司 一种抗衰老益生菌制剂及制备方法
CN107325997B (zh) * 2017-05-28 2020-05-01 广州弘宝元生物科技有限公司 具有头孢抗性且高表达Sir2蛋白的长双歧杆菌及其应用
CN110373368B (zh) * 2019-08-29 2022-05-20 卓源健康科技有限公司 一种长双歧杆菌菌株zj1及其应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011517568A (ja) * 2008-04-15 2011-06-16 ネステク ソシエテ アノニム ビフィドバクテリウム・ロンガム及び海馬ｂｄｎｆ発現
JP2012223134A (ja) 2011-04-20 2012-11-15 Morinaga Milk Ind Co Ltd 生菌数測定方法
WO2019188943A1 (ja) * 2018-03-26 2019-10-03 森永乳業株式会社 脳血流低下の予防及び／又は改善用組成物

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "New Survey Showed GI Health and Anti-Aging Benefits of Morinaga's Probiotics Milk with BB536| Business Wire", MORINAGA MILK INDUSTRY CO., LTD., 19 November 2015 (2015-11-19), pages 2, 3, XP055843510, Retrieved from the Internet <URL:https://www.businesswire.com/news/home/20151119005020/en> [retrieved on 20210107] *
BAKER DJCHILDS BGDURIK MWIJERS MESIEBEN CJZHONG JASALTNESS RJEGANATHAN KBVERZOSA GCPEZESHKI A ET AL., NATURE, vol. 530, 2016, pages 184 - 189
EIJI HARA: "New era of cellular senescence", EXPERIMENTAL MEDICINE, vol. 37, no. 11, 2019, pages 1728 - 1733
F. AMRIT, METHODS, vol. 68, no. 3, 2014, pages 465 - 475
PAEZ-RIBES MGONZALEZ-GUALDA EDOHERTY GJMUNOZ-ESPIN D., EMBO MOLECULAR MEDICINE, vol. 11, no. 12, 2019
R PEREZ-CAMPOM LOPEZ-TORRESS CADENASC ROJASG BARJA, J. COMP. PHYSIOL. B, vol. 168, no. 3, 1998, pages 149 - 158
S. BRENNER, GENETICS, vol. 77, no. 1, 1974, pages 71 - 94
See also references of EP4091673A4
TEZZE CROMANELLO VDESBATS MA, CELL METAB, vol. 25, no. 6, 2017, pages 1374 - 1389
YIQIANG ZHANG ET AL., REDOX BIOL, vol. 11, 2017, pages 30 - 37
YURI ISHII , YUMIKA OKADA , SAYURI MATSUOKA , MANZHEN SHEN, KEI YUI , MASAYUKI YAGI, YOSHIKAZU YONEI: "Effect of supplement containing Silybum marianum extract, soy extract, collagen peptide, bifidobacteria and apple extract on skin: A randomized placebo- controlled, double-blind, parallel group comparative clinical study", GLYCATIVE STRESS RESEARCH, vol. 3, no. 3, 2016, pages 156 - 171, XP055843517 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116694528A (zh) * 2023-06-20 2023-09-05 广东南芯医疗科技有限公司 长双歧杆菌lf04在制备抗氧化和抗衰老产品中的应用
CN118806654A (zh) * 2024-07-17 2024-10-22 慕恩（广州）生物科技有限公司 长双歧杆菌的二裂酵母发酵产物溶胞产物及其在抗氧化及抗紫外中的应用

Also Published As

Publication number Publication date
JPWO2021145113A1 (https=) 2021-07-22
EP4091673A1 (en) 2022-11-23
JP7419404B2 (ja) 2024-01-22
EP4091673A4 (en) 2024-01-31

Similar Documents

Publication Publication Date Title
TWI784953B (zh) 短雙岐桿菌及/或含有其培養物之用途
WO2017130859A1 (ja) 神経細胞死抑制剤
JPWO2018168449A1 (ja) ペプチドグリカン認識タンパク質産生促進用組成物
US12239619B2 (en) Composition for inducing pili formation in bacterium of genus Bifidobacterium
JPWO2020246583A1 (ja) 組成物
WO2019188943A1 (ja) 脳血流低下の予防及び／又は改善用組成物
JP2024049199A (ja) プラズマサイトイド樹状細胞活性化用組成物
JP7339008B2 (ja) 酪酸菌用プレバイオティクス組成物
JP7419404B2 (ja) 抗老化用組成物
JP7431964B2 (ja) ミトコンドリア機能改善用組成物
CN118119286A (zh) 用于促进低聚糖的同化的组合物
JP2021112181A (ja) 老化細胞の蓄積抑制用組成物
JP2021155349A (ja) 腸内細菌叢改善用組成物
WO2024101341A1 (ja) 新生児又は乳幼児のための組成物
JP7368484B2 (ja) 組成物並びに該組成物含有する飲食品組成物および調製乳
JP2024031727A (ja) プラズマサイトイド樹状細胞活性化用組成物
JP2023021731A (ja) 免疫賦活用組成物
CN115803039A (zh) 认知功能改善剂、认知功能维持剂、海马体功能改善剂和海马体功能维持剂
JP2022141436A (ja) 概日リズム改善のための組成物
JP6247185B2 (ja) バイロフィラ属細菌増殖抑制剤及びバイロフィラ属細菌増殖抑制方法
JP2021127321A (ja) 持久力向上用組成物
JP2022156305A (ja) エリスロポエチン産生促進用組成物
WO2023068374A1 (en) Composition for promoting the assimilation of an oligosaccharide
JP2024075260A (ja) 免疫調整用組成物
JP2021134156A (ja) 基礎代謝向上用組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20913307

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2021570686

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020913307

Country of ref document: EP

Effective date: 20220817